Engineered CD25 Polypeptides for Selective Antibody Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing CD25-targeting antibodies often result in unpredictable and undesirable characteristics such as antibody promiscuity or low cross-reactivity across species, necessitating the need for engineered polypeptides that mimic CD25 epitopes outside the IL-2 binding site.
Innovation Solution
Engineered polypeptides with at least 46% structural and/or dynamic identity to specific CD25 reference targets, designed using spatially-associated topological constraints, are used to develop antibodies that specifically bind to CD25 epitopes, avoiding competition with IL-2 and other reference binding agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods of developing CD25 immunogens are used, then antibody production is achieved, but antibody promiscuity and low cross-reactivity across species occur
Solution Approach 1:
The patent creates engineered polypeptides that are simplified copies or mimics of the native CD25 protein epitopes. These engineered immunogens replicate the critical structural features and conformational characteristics of CD25 epitopes without including the entire native protein structure, thereby producing antibodies that specifically recognize CD25 without cross-reacting with other IL-2 receptor components.
Solution Approach 2:
The patent divides the CD25 protein into specific epitopic regions and creates engineered polypeptides that target particular segments (such as the alpha domain epitopes). By focusing on specific segmented regions rather than the whole protein, the immunogens produce antibodies with refined specificity for particular CD25 epitopes, reducing promiscuous binding.
2Adaptability or versatility
If current methods of developing CD25 immunogens are used, then antibody production is achieved, but low cross-reactivity across species occurs
Solution Approach 1:
The patent modifies key structural and conformational parameters of the immunogen design to create engineered polypeptides that preserve the essential epitopic features conserved across species. By optimizing parameters such as backbone conformation, side chain orientation, and structural dynamics rather than sequence identity alone, the immunogens elicit antibodies with improved cross-reactivity while maintaining species-specific specificity.
3Reliability
If engineered polypeptides with high structural identity to CD25 are used, then antibody specificity is improved, but complexity of immunogen design increases
Solution Approach 1:
The patent extracts only the essential epitopic features and conformational characteristics from the native CD25 protein structure to create simplified engineered polypeptides. By taking out and replicating only the critical structural elements necessary for antibody binding (such as specific beta-sheet configurations and side chain arrangements) while omitting non-essential portions, the design achieves high antibody specificity with reduced overall complexity.
Data Source
AI summary
Provided herein engineered polypeptides that comprise a combination of spatially-associated topological constraints, wherein at least one constraint is derived from a CD25 reference target, and methods of selecting said engineered polypeptides. Further provided are methods of using the engineered polypeptides, including as positive and/or negative selection molecules in methods of screening a library of binding molecules such as antibodies. Further provided herein are CD25 antibodies selected using these engineered polypeptides.